key: cord-0879267-8tb8qpvm
authors: Falck-Jones, S.; Vangeti, S.; Yu, M.; Falck-Jones, R.; Cagigi, A.; Badolati, I.; Osterberg, B.; Lautenbach, M. J.; Ahlberg, E.; Lin, A.; Szurgot, I.; Lenart, K.; Hellgren, F.; Salde, J.; Albert, J.; Johansson, N.; Bell, M.; Lore, K.; Farnert, A.; Smed-Sorensen, A.
title: Functional myeloid-derived suppressor cells expand in blood but not airways of COVID-19 patients and predict disease severity
date: 2020-09-09
journal: nan
DOI: 10.1101/2020.09.08.20190272
sha: 41fe77d9ef6364358a1d2831cdd08ff823ab4deb
doc_id: 879267
cord_uid: 8tb8qpvm

The immunopathology of COVID-19 remains enigmatic, exhibiting immunodysregulation and T cell lymphopenia. Monocytic myeloid-derived suppressor cells (M-MDSC) are T cell suppressors that expand in inflammatory conditions, but their role in acute respiratory infections remains unclear. We studied blood and airways of COVID-19 patients across disease severity at multiple timepoints. M-MDSC frequencies were elevated in blood but not in nasopharyngeal or endotracheal aspirates of COVID-19 patients compared to controls. M-MDSCs isolated from COVID-19 patients suppressed T cell proliferation and IFN{gamma} production partly via an arginase-1 (Arg-1) dependent mechanism. Furthermore, patients showed increased Arg-1 and IL-6 plasma levels. COVID-19 patients had fewer T cells, and displayed downregulated expression of the CD3{zeta} chain. Ordinal regression showed that early M-MDSC frequency predicted subsequent disease severity. In conclusion, M-MDSCs expand in blood of COVID-19 patients, suppress T cells and strongly associate with disease severity, suggesting a role for M-MDSCs in the dysregulated COVID-19 immune response.

The pathogenesis of COVID-19 caused by severe acute respiratory syndrome 44 coronavirus-2 (SARS-CoV-2) remains elusive. SARS-CoV-2 infection ranges from 45 asymptomatic disease to multi-organ failure and death 1 . COVID-19 is characterized by 46 influenza-like symptoms (including fever, cough and myalgia), and in severe cases, 47 respiratory failure and acute respiratory distress syndrome, occurring in around 40% 48 of hospitalized cases 1, 2, 3 . Fatal COVID-19 is caused by tissue-directed 49 immunopathology, especially in the lungs, rather than the virus itself 4, 5 . Furthermore, 50 it is known that immune cells differ depending on their anatomical location 6, 7, 8, 9, 10 . 51 Therefore, studying both systemic and respiratory immune responses in COVID-19 is 52 important to fully understand its pathogenesis and to identify factors dictating disease 53 severity. 54 55 COVID-19 is associated with substantial immune activation including elevated levels 56 of proinflammatory cytokines such as IL-6 11 . Furthermore, T cell lymphopenia occurs, 57 especially in critical cases 12 , but the underlying mechanism(s) remain unclear. SARS-58

CoV-2 specific T cells are important in combating the virus 13 , and a functional T cell 59 response is critical for clearing infections in general. Myeloid-derived suppressor cells 60 (MDSCs) are myeloid immune cells with an immature phenotype and potent T cell 61 suppressive capacity 14, 15, 16 In this study, we investigated M-MDSCs in COVID-19 patients across disease severity 79 and compared to influenza patients and healthy controls. Influenza A virus infection is 80 often compared to COVID-19 due to similarities including the diverse clinical 81 presentation and the route of transmission 23, 24 . We found a striking association 82 between the frequency of blood M-MDSCs and COVID-19 disease severity. However, 83 the frequency of M-MDSCs from the nasopharynx and lower airways did not correlate 84 with disease severity in COVID-19. Importantly, purified M-MDSCs were functional and 85 suppressed T cell proliferation, partly via an Arg-1 dependent mechanism. In line with 86 this, plasma Arg-1 levels were elevated in COVID-19 patients in a disease severity 87 dependent manner. Finally, we found that early frequency of blood M-MDSCs 88 predicted subsequent disease severity, suggesting both that M-MDSCs are involved 89 in the dysregulation of the immune response in COVID-19 and that they may be used 90 as a potential prognostic marker in COVID-19 patients. 91 92 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.08.20190272 doi: medRxiv preprint

In total, 147 adults with PCR confirmed SARS-CoV-2 infection, ranging from mild to 95 fatal disease were enrolled in the study: 91 patients from hospital wards, 43 patients 96 from the ICU, 3 patients from an outpatient clinic and 10 household contacts, and blood 97 as well as respiratory samples were collected longitudinally ( Figure 1A and 98

Supplementary figure 1). Identical samples from 44 patients with PCR confirmed 99 influenza A virus infection with mild to moderate disease, as well as from 33 age-100 matched healthy controls (HCs) were included for comparison ( Figure 1B and Table  101 1). As expected, disease severity in the COVID-19 patient cohort varied over time 102 ( Figure 1C , Table 2 and Supplementary figure 1), and some patients deteriorated 103 during their hospital stay. At peak disease severity, 13% of patients were classified as 104 having mild disease, 39% as moderate, and 39% as severe ( Figure 1C ). Furthermore, 105 there were 12 recorded fatalities (8.1%) in the COVID-19 cohort during the observation 106 period ( Figure 1C ). The peak disease severity score prior to death was 6 in all but two 107 patients who had scores of 4 and 5 respectively. At the end of the study period, 110 of 108 the non-fatal, hospitalized patients had been discharged while 12 patients remained in 109 hospital all of whom were already classified as having severe disease. The distribution 110 of age varied significantly across peak disease severity groups in COVID-19 patients 111 (p<0.001), as did body mass index (BMI) (p<0.001), male gender (p=0.004), and CCI 112 (p=0.042) ( Table 2) . 113 p=0.0016 (data now shown). In contrast to NPA, COVID-19 patients with more severe 131 disease had significantly higher peak M-MDSC frequencies in blood, while COVID-19 132 patients with mild disease had blood M-MDSC frequencies comparable to those seen 133 in HCs ( Figure 2C ). The frequency of M-MDSC in blood from COVID-19 patients 134 decreased over time ( Figure 2D ) and returned to similar frequencies as seen in HCs 135 at follow up samples taken during convalescence (33-65 days after study inclusion) 136 ( Figure 2E ). 137 138 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 9, 2020. . https: //doi.org/10.1101 //doi.org/10. /2020 Somewhat surprisingly, COVID-19 patients, in contrast to influenza patients, had low 139 frequencies of M-MDSCs in NPA, even when comparing patients with similar severity 140 of disease ( Figure 2B ). Since COVID-19 patients on average were included in the 141 study and sampled significantly later after onset of symptoms compared to the 142 influenza patients (18 vs 5 days, respectively), we speculated that the infection- perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.08.20190272 doi: medRxiv preprint suppression of both CD4 and CD8 T cell proliferation in a dose-dependent manner 164 ( Figure 3A -C). In line with this, SEB induced high levels of IFNg secretion that were 165 significantly lower in co-cultures with M-MDSCs present ( Figure 3D ). Arginase 1 (Arg-166 1) production is one effector mechanism by which M-MDSCs suppress T cell 167 proliferation via degradation of L-arginine that is needed for proliferation. Indeed, 168 addition of L-arginine to the M-MDSC co-cultures restored the concentration of IFNg in 169 the cell culture supernatants ( Figure 3D ). Furthermore, co-cultures with M-MDSCs 170 contained high levels of Arg-1 that was undetectable in cultures without M-MDSCs 171 ( Figure 3E ). In co-cultures supplemented with L-arginine, Arg-1 was no longer 172 detectable, possibly due to complex formation of Arg-1 and the substrate 25 ( Figure 3E patients had significantly higher levels of Arg-1 than HCs, but no significant difference 186 was observed between COVID-19 patients and influenza patients ( Figure 4A ). 187

Interestingly, Arg-1 levels in NPA were higher than in plasma in all three groups, with 188 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.08.20190272 doi: medRxiv preprint no significant differences between the groups ( Figure 4B ). Among COVID-19 patients, 189 the plasma concentration of Arg-1 was lower in patients with mild disease compared 190 to patients with moderate, severe and fatal disease (p=0.07, p=0.04 and p=0.01 191 respectively) ( Figure 4C perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 9, 2020. Figure 6A ). This yielded a crude odds ratio (OR) of 1.50 (95% CI 1.03 -2.32), 238 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.08.20190272 doi: medRxiv preprint indicating that the M-MDSC frequency in the first two weeks from onset of symptoms 239 could potentially be a predictor of more severe outcome of COVID-19 ( Figure 6B ). 240 241 As shown above, M-MDSC frequency was higher in COVID-19 patients with more 242 severe disease ( Figure 2C ), and these patients were both predominantly male and had 243 a significantly higher age compared to COVID-19 patients with less severe disease 244 (Table 1) . Therefore, the association between M-MDSC frequency and sex and age In summary, early M-MDSC frequencies are associated with subsequent disease 250 severity and appear to be strongly associated with age and sex. 251 252 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.08.20190272 doi: medRxiv preprint

Understanding the immunopathogenesis of COVID-19 is critical to optimally treat 254 patients and prevent fatal outcome but also to aid in the development of specific 255 therapy and vaccines. One potential player in the immune activation to SARS-CoV-2 256 infection may be MDSCs, a subset of immune cells that in recent years have been 257 intensively studied, by us and others, mainly in relation to cancer and vaccination 14, 15, 258 16, 18, 27 . perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 9, 2020. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 9, 2020. . https://doi.org/10. 1101 to HCs in plasma. There was also a connection between disease severity and Arg-1 303 level in plasma, although there was no difference between patients with moderate 304 disease to fatal outcome. Interestingly, Arg-1 levels were in general substantially 305 higher in NPA than in plasma for all cohorts, without any association with M-MDSC 306 frequency in NPA. It is known that Arg-1 is constitutively produced in the airways in 307 bronchial epithelial cells, endothelial cells, myofibroblasts and alveolar macrophages. 308

The function, however, is unknown. Arg-1 has been suggested to be involved in disease, but the underlying mechanisms for the decrease are still unknown 38 . One 326 potential such mechanism could be the downregulation of CD3ζ chain, that results in 327 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 9, 2020. that identify a population likely to be M-MDSCs that is associated with severe COVID-344 19 21 . Previous research has shown age and male gender are risk factors for severe 345 COVID-19 42 . Furthermore, it is known that MDSCs increase with age as part of the 346 "inflammaging" process (the inflammation seen in ageing) 43 , but little is known about 347 gender differences. In line with this, we found a correlation between M-MDSC 348 frequency and both age and male gender in this cohort, possibly partly explaining the 349 increased morbidity seen in men and older patients. 350 351 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 9, 2020. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 9, 2020. Fraction of inspired oxygen (FiO2) estimation based on O2 flow was done in 387 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 9, 2020. were subsequently categorized based on the peak respiratory SOFA or mSOFA value. 390

The 5-point respiratory SOFA score was then extended with an additional level to 391 distinguish admitted mild cases from non-admitted mild cases. Finally, fatal outcome 392 was added as a seventh level, with peak disease severity score 6 prior to death in all 393 but two patients who had scores of 4 and 5, respectively. Additionally, the resulting 7-394 point composite peak severity score was condensed into a classification consisting of 395 mild (1-2), moderate (3-4), severe (5-6), and fatal (7) containing tubes from all non-ICU patients and controls. In ICU patients, blood was 407 pooled from heparin-coated blood gas syringes discarded in the last 24 hours. In some 408 ICU patients, additional venous blood samples were also collected in EDTA tubes. 409

Routine clinical chemistry analysis was performed on all study subjects including HCs. 410

Admitted patients were sampled at up to four timepoints and discarded ICU patient 411 material was collected up to ten timepoints. 412 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.08.20190272 doi: medRxiv preprint perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 9, 2020. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 9, 2020. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 9, 2020. . https://doi.org/10. 1101 Detection was performed with a goat anti-human IgG HRP-conjugated secondary 488 antibody (clone G18-145 from BD Biosciences) followed by incubation with TMB 489 substrate (BioLegend; cat# 421101) and stopped with a 1M solution of H2SO4. 490 Absorbance was read at 450nm+550nm background correction using an ELISA flow-cytometry data were assumed to have a standard distribution and means were 499 compared using either an independent Student's t-test or a one-way analysis of 500 variance (ANOVA). Nominal patient characteristics were compared between groups 501 using a Pearson Chi-Squared test or Fisher's exact test depending on if the expected 502 count of any cell was above or below five. Cytokine and flow cytometry data were 503 presumed to have a non-standard distribution and medians were thus compared using 504 the Wilcoxon-Mann-Whitney U or Kruskal-Wallis tests depending on number of 505 cohorts. Post-hoc testing after Kruskal-Wallis was performed using Dunn's test of 506 multiple comparisons or by controlling the False Discovery Rate using Benjamini, 507

Krieger and Yekutieli's an adaptive linear step-up procedure. Non-parametric 508 comparisons of dependent data were performed using Wilcoxon's Signed Ranks test. 509

For correlation analyses of continuous data, Spearman's Rho was used. Finally, a 510

proportional odds logistic regression model was constructed to evaluate predictive 511 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.08.20190272 doi: medRxiv preprint capacity of M-MDSC frequencies on disease severity. A 95% significance level was 512 used throughout the study. 513 514 Missing daily severity score data was approximated using a last-observation-carried-515 forward (LOCF) method. For flow cytometry data, the peak M-MDSC frequency and 516 lowest T cell count were extracted. The peak value for routine laboratory analyses was 517 extracted separately for each analysis except in the case of blood differential counts in 518 which all counts were extracted for the timepoint of lowest lymphocyte count. The 519 ordinal logistic regression model was based on a subset of patients with M-MDSC-520 frequencies sampled within two weeks of onset of symptoms and before potential ICU 521 admission and who had a disease severity score less than five on the day of sampling. 522

In the event of multiple timepoints for one patient during that period, peak M-MDSC-523 frequency was used. 524 525 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.08.20190272 doi: medRxiv preprint Acknowledgments 526 We thank the patients and healthy volunteers who have contributed to this study. We 527 would also like to thank medical students and hospital staff for assistance with patient 528 sampling and collection of clinical data. This work was supported by grants from the 529 Swedish Research Council, the Swedish Heart-Lung Foundation, the Bill and Melinda 530

Gates Foundation, the Knut and Alice Wallenberg Foundation and Karolinska Institutet. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 9, 2020. Abbreviations: BMI = body mass index, CCI = Charlson co-morbidity index, CRP = Creactive protein, WBC = White blood count. Normal range: CRP <3 mg/L, WBC 3.5-8.8x10 9 /L, lymphocytes 1.1-3.5 x10 9 /L, neutrophils 1.6-5.9 x10 9 /L, monocytes 0.2-0.8 x10 9 /L. Onset to inclusion, days, mean 18 (10) 5 (2) -*** Co-morbidities CCI, mean (SD) 2 (2) 2 (2) -ns BMI, mean (SD) 28.5 (4.6) 26.7 (4.9) 25.0 (3.3) * Hypertension, n (%) 55 (38%) 14 (33%) 0 ns Diabetes, n (%) 34 (23%) 4 (9.1%) 0 ns Current smoker, n (%) 10 (7.0%) 7 (16%) 0 ns Lab analyses CRP (mg/L), mean (SD) 1,2 206 (134) 119 (146) 2 (3) *** WBC (x10 9 /L), mean (SD) 1,3 8.0 (4.3) 6.8 (3.5) 6.5 (1.5) ns Lymphocytes (x10 9 /L), mean (SD) 1,3 0.89 (0.69) 1.06 (0.47) 2.41 (1.24) *** Neutrophils (x10 9 /L), mean (SD) 1,3 6.4 (3.9) 5.1 (3.5) 3.1 (0.7) ** Monocytes (x10 9 /L), mean (SD) 1,3 0.44 (0.27) 0.64 (0.35) 0.54 (0.24) ** Outcome Peak severity score 4 , mean (SD) 4.49 (1.65) 1.80 (0.82) -*** Fatal outcome 12 (8.1) 0 0

All rights reserved. No reuse allowed without permission.

perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.08.20190272 doi: medRxiv preprint Table 2 . Baseline characteristics of COVID-19 patients across disease severity.

Clinical course and risk factors for mortality of adult inpatients 549 with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical features of patients infected with 2019 novel 553 coronavirus in Wuhan

Risk Factors Associated With Acute Respiratory Distress 556 Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia 557 in Wuhan, China

Pulmonary Vascular Endothelialitis, Thrombosis, and 560 Angiogenesis in Covid-19

Immunology of COVID-19: Current State of the Science

Dendritic Cells and Monocytes with Distinct Inflammatory 566 Responses Reside in Lung Mucosa of Healthy Humans

Human Blood and Tonsil Plasmacytoid Dendritic Cells 570 Display Similar Gene Expression Profiles but Exhibit Differential Type I IFN 571 Responses to Influenza A Virus Infection

Flow Cytometric Analysis of Myeloid Cells in Human Blood

Anatomical location determines the distribution and 578 function of dendritic cells and other APCs in the respiratory tract

Flow Cytometric Analysis of Mononuclear Phagocytes in 582 Nondiseased Human Lung and Lung-Draining Lymph Nodes

An inflammatory cytokine signature helps predict COVID-586 19 severity and death

Pathological inflammation in patients with COVID-19: 590 a key role for monocytes and macrophages

Robust T cell immunity in convalescent individuals with 597 14. Gabrilovich, D.I. & Nagaraj, S. Myeloid-derived suppressor cells as regulators 598 of the immune system

Deciphering myeloid-derived suppressor cells: isolation and 601 markers in humans, mice and non-human primates

Rhesus Macaque Myeloid-Derived Suppressor Cells Demonstrate 605 T Cell Inhibitory Functions and Are Transiently Increased after Vaccination

Effect of TLR agonists on the differentiation and function of 609 human monocytic myeloid-derived suppressor cells

The Nature of Myeloid-613 Derived Suppressor Cells in the Tumor Microenvironment

How to measure the immunosuppressive activity of MDSC: 617 assays, problems and potential solutions

Suppressive myeloid cells are a hallmark of 621 severe COVID-19

Perturbations in the mononuclear phagocyte landscape 625 associated with COVID-19 disease severity

Expansion of myeloid-derived suppressor cells in patients with 629 severe coronavirus disease (COVID-19)

Comparison of Hospitalized Patients With ARDS Caused by 632 COVID-19 and H1N1

Comparing SARS-CoV-2 with SARS-CoV and influenza 635 pandemics

L-Arginine regulates the expression of the T-cell receptor zeta 641 chain (CD3zeta) in Jurkat cells

Recommendations for myeloid-derived suppressor cell 644 nomenclature and characterization standards

Complex Immune Dysregulation in COVID-647 19 Patients with Severe Respiratory Failure

Myeloid-Derived Suppressor Cells in Infection: A 651 General Overview

Myeloid-Derived Suppressor Cells in 654

Mucosal immune responses predict clinical outcomes 657 during influenza infection independently of age and viral load

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 661 and Is Blocked by a Clinically Proven Protease Inhibitor

SARS-CoV-2 Reverse Genetics Reveals a Variable Infection 665 Gradient in the Respiratory Tract

HIF-1α regulates function and differentiation of myeloid-668 derived suppressor cells in the tumor microenvironment

Plasticity of myeloid-672 derived suppressor cells in cancer

Traffic signals for lymphocyte recirculation and leukocyte 675 emigration: the multistep paradigm

Cytokine storm and leukocyte 678 changes in mild versus severe SARS-CoV-2 infection: Review of 3939 679 COVID-19 patients in China and emerging pathogenesis and therapy 680 concepts

The clinical course and its correlated immune status in COVID-19 683 pneumonia

Neutrophils with myeloid derived suppressor function deplete 686 arginine and constrain T cell function in septic shock patients

Myeloid-derived suppressor cells are associated with viral 690 persistence and downregulation of TCR ζ chain expression on CD8(+) T cells 691 in chronic hepatitis C patients

Increased myeloid-derived suppressor cells in gastric cancer 694 correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins

Risk factors of critical & mortal COVID-19 cases: A systematic 698 literature review and meta-analysis

The role of myeloid-derived 701 suppressor cells (MDSC) in the inflammaging process

The SOFA (Sepsis-related Organ Failure Assessment) 705 score to describe organ dysfunction/failure. On behalf of the Working Group 706 on Sepsis-Related Problems of the European Society of Intensive Care 707 Medicine

A modified sequential organ failure assessment score for 710 critical care triage

A new method of 713 classifying prognostic comorbidity in longitudinal studies: development and 714 validation

Statistics performed: One-way ANOVA, Fisher's exact test. 2 days, 3 Peak values: CRP, PCT; Nadir values: lymphocyte count

WBC, neutrophil and monocyte counts at timepoint for lowest lymphocyte count

BMI= body mass index, CCI = Charlson co-morbidity index, ACE-I = angiotensin converting enzymeinhibitor, CRP = C-reactive protein, PCT = procalcitonin, WBC = white blood cell count. Normal range: CRP <3 mg/L